Nanotechnology-Enabled Topical Drug Delivery for Trigeminal Neuralgia: Current Status and Future Directions

Trigeminal neuralgia (TN) is a severely incapacitating condition marked by recurring bouts of intense, short-lived, electric shock-like face pain. In order to better characterize patients and aid in the decision-making process regarding medicinal and surgical therapies, new diagnostic criteria that subclassify TN based on the existence of trigeminal neurovascular conflict or an underlying neurological condition should be implemented. The diagnostic work-up should include MR imaging, especially high-resolution trigeminal sequences. The preferred medications are oxcarbazepine and carbamazepine. Botulinum toxin type A, baclofen, gabapentin, pregabalin, and lamotrigine can be taken either on their own or in combination with other medications. If the medicinal therapies are not well accepted or the pain is not well managed, surgery should be considered. For patients with trigeminal neurovascular conflict, trigeminal microvascular decompression is the first-line surgical procedure. If MR imaging reveals no neurovascular contact, or if patients are deemed too weak for microvascular decompression or do not want to take the risk, neuroablative surgical treatments may be available.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24333842
Primary Topic
Trigeminal Neuralgia and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nanotechnology-Enabled Topical Drug Delivery for Trigeminal Neuralgia: Current Status and Future Directions

Neha Patil, S.P. Pawar, Mrunal D. Pendharkar, Sanket Patil
Zenodo (CERN European Organization for Nuclear Research)
Trigeminal Neuralgia and Treatments
article

Nanotechnology-Enabled Topical Drug Delivery for Trigeminal Neuralgia: Current Status and Future Directions

Neha Patil, S.P. Pawar, Mrunal D. Pendharkar, Sanket Patil
article en

Abstract

Trigeminal neuralgia (TN) is a severely incapacitating condition marked by recurring bouts of intense, short-lived, electric shock-like face pain. In order to better characterize patients and aid in the decision-making process regarding medicinal and surgical therapies, new diagnostic criteria that subclassify TN based on the existence of trigeminal neurovascular conflict or an underlying neurological condition should be implemented. The diagnostic work-up should include MR imaging, especially high-resolution trigeminal sequences. The preferred medications are oxcarbazepine and carbamazepine. Botulinum toxin type A, baclofen, gabapentin, pregabalin, and lamotrigine can be taken either on their own or in combination with other medications. If the medicinal therapies are not well accepted or the pain is not well managed, surgery should be considered. For patients with trigeminal neurovascular conflict, trigeminal microvascular decompression is the first-line surgical procedure. If MR imaging reveals no neurovascular contact, or if patients are deemed too weak for microvascular decompression or do not want to take the risk, neuroablative surgical treatments may be available.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Trigeminal Neuralgia and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon